Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 122

Sort by

Sort Order Select

Journal Articles

BCR-ABL1 p190 in CML: A Minor Breakpoint with a Major Impact

Shady Adnan Awad, MD, Helena Hohtari, MD, Komal Kumar Javarappa, PhD, Tania Brandstoetter, Daehong Kim, Swapnil Potdar, MSc, Caroline A Heckman, PhD, Soili Kytölä, PhD, Kimmo Porkka, Eszter Doma, PhD, Veronika Sexl, MD PhD, Matti Kankainen, PhD, Satu Mustjoki, MD PhD

Blood (2019) 134 (Supplement_1): 190.

https://doi.org/10.1182/blood-2019-126584

Published: 2019

Journal Articles

Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR

Zaid Abdel Rahman, MD, Nicole Gannon, PA-C, Megan Melody, MD, Paul Muniz, RN, Ernesto Ayala, MD, Vivek Roy, MD, Lisa Brumble, Sikander Ailawadhi, MD, Taimur Sher, MD, James M. Foran, MD, Hemant S. Murthy, MD, Han W. Tun, MD, Candido E. Rivera, MD, Asher A. Chanan-Khan, MD, Abba C. Zubair, MD PhD, Mohamed A Kharfan-Dabaja, MDMBA

Blood (2019) 134 (Supplement_1): 5610.

https://doi.org/10.1182/blood-2019-122067

Published: 2019

Journal Articles

TET2 Loss Accelerates Leukemogenesis By Disrupting Mismatch Repair Proteins

Blood (2019) 134 (Supplement_1): 1200.

https://doi.org/10.1182/blood-2019-132005

Published: 2019

Journal Articles

IPO11 Is Upregulated in Relapsed AML and Supports Survival of Leukemic Stem Cells

Boaz Nachmias, MD PhD, Veronique Voisin, PhD, Rose Hurren, BSc, Xioaming Wang, Neil Maclean, G. Wei Xu, Ayesh K Seneviratne, BSc, MSc, Changjiang Xu, Gary D Bader, Liran I. Shlush, MD, Aaron D Schimmer, MD PhD

Blood (2019) 134 (Supplement_1): 2530.

https://doi.org/10.1182/blood-2019-122284

Published: 2019

Journal Articles

ANTI-PD-1 Treatment in a Family with Constitutional Mismatch Repair Deficiency Syndrome with Multiple Cancers from Turkey. Is Cancer Immunoprevention with Checkpoint Inhibitors HAS a Role in CASES with Homozygous Mutationis

Emel Unal, Derya Ozyoruk, Nurdan Tacyildiz, Ferda Pi̇narli̇, A Erdogan, S Hanalioglu, Arzu Erdem, Meral Beksac, MD

Blood (2019) 134 (Supplement_1): 5632.

https://doi.org/10.1182/blood-2019-130102

Published: 2019

Journal Articles

Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS

Cassandra M. Hirsch, Wenyi Shen, MD, Bartlomiej P. Przychodzen, Yasunobu Nagata, Vera Adema, PhD, Teodora Kuzmanovic, BA, Louis Williams, MD MBA, Aziz Nazha, Valeria Visconte, PhD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski

Blood (2018) 132 (Supplement 1): 3074.

https://doi.org/10.1182/blood-2018-99-116535

Published: 2018

Journal Articles

The Evolution of Genetic Aberrations in CML Patients Harboring a Ph-Negative Clone: A 6-Year Follow-up Study of 52 Patients

Constance Baer, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2018) 132 (Supplement 1): 3002.

https://doi.org/10.1182/blood-2018-99-112061

Published: 2018

Journal Articles

Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells

Blood (2018) 132 (Supplement 1): 4246.

https://doi.org/10.1182/blood-2018-99-119974

Published: 2018

Journal Articles

RUNX1 Mutations Identify an Entity of Blast Phase Chronic Myeloid Leukemia (BP-CML) Patients with Distinct Phenotype, Transcriptional Profile and Drug Vulnerabilities

Shady Awad, MD, Matti Kankainen, PhD, Olli Dufva, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Satu Mustjoki, MD PhD

Blood (2018) 132 (Supplement 1): 4257.

https://doi.org/10.1182/blood-2018-99-111602

Published: 2018

Journal Articles

Molecular monitoring in CML: how deep? How often? How should it influence therapy?

Naranie Shanmuganathan, Timothy P. Hughes

Blood (2018) 132 (20): 2125–2133.

https://doi.org/10.1182/blood-2018-05-848630

Published: 2018

Journal Articles

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Blood (2018) 132 (4): 393–404.

https://doi.org/10.1182/blood-2016-09-739086

Published: 2018

Includes: Supplemental data

Journal Articles

Incidence of Low Level Mutations in Newly Diagnosed CML Patients: A Substudy of the German Tiger Trial

Georg-Nikolaus Franke, MD, Jacqueline Maier, PhD, Kathrin Wildenberger, Christine Günther, Michael Cross, PhD, Thomas Ernst, MD, Christian Fabisch, PhD, Dietger Niederwieser, MD, Andreas Hochhaus, MD, Thoralf Lange, MD

Blood (2017) 130 (Supplement 1): 252.

https://doi.org/10.1182/blood.V130.Suppl_1.252.252

Published: 2017

Journal Articles

No Association between Relapse Risk and Thiopurine Methyltransferase Activity By Either Geno- or Phenotype in the NOPHO ALL-2008 Protocol

Stine Nygaard Nielsen, PhD MD, Kathrine Grell, PhD, Jacob Nersting, PhD, Jonas Abrahamsson, MD PhD, Bendik Lund, MD PhD, Jukka A. Kanerva, MD, Ólafur G Jónsson, MD, Goda Vaitkeviciene, MD, Kaie Pruunsild, MD, Malin Lindqvist Appell, Lisa Hjalgrim, PhD, Kjeld Schmiegelow, MD DMSc

Blood (2017) 130 (Supplement 1): 1279.

https://doi.org/10.1182/blood.V130.Suppl_1.1279.1279

Published: 2017

Journal Articles

Identification of Progression-Associated Mutations in Chronic Myeloid Leukemia (CML) By Comparative Genomic Analysis

Shady Adnan Awad, MD, Matti Kankainen, PhD, Samuli Eldfors, Bhagwan Yadav, PhD, Soili Kytölä, Pekka Ellonen, Mahmoud Kamel, MD PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Satu Mustjoki, MDPhD

Blood (2017) 130 (Supplement 1): 250.

https://doi.org/10.1182/blood.V130.Suppl_1.250.250

Published: 2017

Journal Articles

SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications

Blood (2017) 130 (Supplement 1): 2944.

https://doi.org/10.1182/blood.V130.Suppl_1.2944.2944

Published: 2017

Journal Articles

Imatinib (IM) in Combination with Hydroxyurea Showed Significantly Lower Major Molecular Response Rates at 6 Months but Similar MMR at 18 Months in Patients with CML1st CP Compared to IM Alone. Final Results of the CML2004 Study. NCT 02480608

Thoralf Lange, MD, Rainer Krahl, PhD, Ulrich von Grünhagen, MD, Haifa Kathrin Al-Ali, Schwarzer Andreas, MD, Kathleen Jentsch-Ulrich, MD, Claudia Spohn, MD, Volker Lakner, MD, Michael Assmann, MD, Christian Junghanss, MD, Markus Pfirrmann, Arthur Gil, PhD, Rüdiger Hehlmann, MD, Michael W. Deininger, MD PhD, Dietger Niederwieser, MD

Blood (2017) 130 (Supplement 1): 1615.

https://doi.org/10.1182/blood.V130.Suppl_1.1615.1615

Published: 2017

Journal Articles

TET2 and MSH6: A Novel Role for MMR in the Pathogenesis of Myeloid Malignancies

Edward F Greenberg, MD, Cassandra M. Hirsch, BS, Feng Pan, PhD, Babal K Jha, PhD, Yihong Guan, PhD, Valeria Visconte, PhD, Dewen You, PhD, Guangbo Qu, PhD, Amy Graham, Bartlomiej P. Przychodzen, MSc, Thomas Laframboise, PhD, Hideki Makishima, MD PhD, Daniel Gackowski, PhD, Ryszard Ólinski, Professor, Yu-Wei Cheng, PhD, Mikkael A. Sekeres, MD MS, Mingjiang Xu, MDPhD, Jaroslaw P. Maciejewski, PhD MD FACP

Blood (2017) 130 (Supplement 1): 1668.

https://doi.org/10.1182/blood.V130.Suppl_1.1668.1668

Published: 2017

Journal Articles

Treatment Free Remission (TFR) in Chronic Myeloid Leukaemia (CML): The Tawam Hospital Experience

Arif Alam, MBBS, Imran Mirza, MBBS FRCPC, Khaled al Qawasmeh, Ali Rababa'H, Hani Osman, MBBS, FRCP, Sabir Hussain, MBBS FRCP, Amar Lal, MBBS FCPS MRCP, Jorgen Kristensen, MD PhD

Blood (2017) 130 (Supplement 1): 5263.

https://doi.org/10.1182/blood.V130.Suppl_1.5263.5263

Published: 2017

Journal Articles

CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors

Amy Hughes, Jade Clarson, Carine Tang, Ljiljana Vidovic, Deborah L. White, Timothy P. Hughes, Agnes S. M. Yong

Blood (2017) 129 (9): 1166–1176.

https://doi.org/10.1182/blood-2016-10-745992

Published: 2017

Includes: Supplemental data

Journal Articles

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

Blood (2017) 129 (7): 846–854.

https://doi.org/10.1182/blood-2016-09-742205

Published: 2017

NARROW

BCR-ABL1 p190 in CML: A Minor Breakpoint with a Major Impact

Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR

TET2 Loss Accelerates Leukemogenesis By Disrupting Mismatch Repair Proteins

IPO11 Is Upregulated in Relapsed AML and Supports Survival of Leukemic Stem Cells

ANTI-PD-1 Treatment in a Family with Constitutional Mismatch Repair Deficiency Syndrome with Multiple Cancers from Turkey. Is Cancer Immunoprevention with Checkpoint Inhibitors HAS a Role in CASES with Homozygous Mutationis

Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS

The Evolution of Genetic Aberrations in CML Patients Harboring a Ph-Negative Clone: A 6-Year Follow-up Study of 52 Patients

Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells

RUNX1 Mutations Identify an Entity of Blast Phase Chronic Myeloid Leukemia (BP-CML) Patients with Distinct Phenotype, Transcriptional Profile and Drug Vulnerabilities

Molecular monitoring in CML: how deep? How often? How should it influence therapy?

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Incidence of Low Level Mutations in Newly Diagnosed CML Patients: A Substudy of the German Tiger Trial

No Association between Relapse Risk and Thiopurine Methyltransferase Activity By Either Geno- or Phenotype in the NOPHO ALL-2008 Protocol

Identification of Progression-Associated Mutations in Chronic Myeloid Leukemia (CML) By Comparative Genomic Analysis

SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications

Imatinib (IM) in Combination with Hydroxyurea Showed Significantly Lower Major Molecular Response Rates at 6 Months but Similar MMR at 18 Months in Patients with CML1st CP Compared to IM Alone. Final Results of the CML2004 Study. NCT 02480608

TET2 and MSH6: A Novel Role for MMR in the Pathogenesis of Myeloid Malignancies

Treatment Free Remission (TFR) in Chronic Myeloid Leukaemia (CML): The Tawam Hospital Experience

CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only